
-
Amarin Corporation NasdaqCM:AMRN Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin 2, Ireland.
Location: One Central Plaza, Dublin 2, D02 K7K5, Ireland | Website: https://www.amarincorp.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.566B
Cash
281.8M
Avg Qtr Burn
-7.72M
Short % of Float
0.15%
Insider Ownership
1.70%
Institutional Own.
18.22%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Icosapent Etheyl (generic Vascepa) Details Triglycerides, Heart disease, Cardiovascular disease | Approved Update | |
Vascepa (icosapent ethyl) Details Triglycerides, Heart disease, Cardiovascular disease | Approved Quarterly sales | |
Vascepa (icosapent ethyl) Details Infectious disease, COVID-19 | Failed Discontinued |